
UBiqube
Unit 2 Blackhall Green, Blackhall Place, Dublin 7, Dublin, D07 TK88, Ireland
Overview
UBiqube is a Dublin-based infrastructure automation and orchestration vendor providing integrated automation across networking, cloud and security technologies. Its flagship orchestration software, the MSActivator™, is a domain-neutral DevOps platform for designing integrated automation processes spanning cloud to core to edge. The MSActivator™ has been used to design and deploy automation workflows in managed security services, security automation (auto-remediation), cloud orchestration, SD‑WAN, smart city applications, network orchestration and other domains. Led by CEO Nabil Souli, the company maintains a global sales and engineering presence. UBiqube said it will use new funding to further accelerate its global expansion. The company is headquartered in Dublin, Ireland. UBiqube developed the MSActivator™, a DevOps-enabled open framework for the design, automation, and orchestration of services over hybrid communication infrastructures including SDN, NFV, and IoT. The MSActivator merges service provisioning, assurance, security reporting, analytics, workflow design, and customer-facing orchestration portals for full lifecycle management. The company positions itself as a vendor-independent orchestration leader and aims to democratize service design over networking and security to reduce premium pricing in management software. The Series A financing will be dedicated to continued technology development and the expansion of sales and marketing forces. UBiqube plans to build a global ecosystem of partners trained and certified to design service automation solutions on the MSActivator framework. The company is headquartered in Dublin and has offices in France, India, the UAE, Japan, and Silicon Valley.
- Total raised
- $20M
- Funding rounds
- 2
- Latest round
- Series B
- Latest activity
- Apr 2019
Industries
- Cloud Infrastructure
- DevOps
- Information Services
- Information Technology
- Network Security
- Software
Recent funding
Series B
Apr 2019
$20M